ProQR Therapeutics N.V.
No SEC Form 4 filings for $PRQR in the last 30 days.
See all $PRQR insider activity →Chardan Capital maintained a Buy rating on ProQR Therapeutics (PRQR) with a $3.00 price target, implying 80.7% upside from the Sep 30 close of $1.66. The firm cited the company's strong clinical pipeline, including AX-0811, and expert validation of its therapies for genetic disorders.
H.C. Wainwright reduced its price target for ProQR Therapeutics (NASDAQ:PRQR) to $8.00 from $12.00, citing execution risks and regulatory uncertainties. The stock is currently trading at $1.66, down 18% year-to-date. ProQR presented initial data for AX-0810, showing promising safety and biomarker engagement. Analysts maintain a positive outlook, with BofA Securities and Citizens also assigning Buy ratings and $8.00 price targets.
ProQR Therapeutics (PRQR) reported Q2 2026 results, including a net loss of €8.7M and first clinical validation of its Axiomer platform. The company raised $59.2M in June and expects cash to last through mid-2028. AX-0810 showed promising Phase 1 data, and AX-0811 data is due by year-end. PRQR shares are up 7.28% to $2.38.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning PRQR (ProQR Therapeutics N.V.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.
Recent PRQR coverage spans insider activity, financial news and earnings.
Analyst upgrade with a higher price target may drive buying interest.
Analyst target cut suggests near-term downside pressure on PRQR.
Positive trial data and improved cash runway may boost PRQR share price.
Analyst initiation suggests strong upside potential for PRQR.
Positive Phase 1 data and fresh capital likely boost short-term upside, but early-stage biotech risk remains.
AlphAI scores every news story that mentions PRQR with an AI model for sentiment and relevance, and aggregates insider trades from ProQR Therapeutics N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Chardan Capital maintained a Buy rating on ProQR Therapeutics (PRQR) with a $3.00 price target, implying 80.7% upside from the Sep 30 close of $1.66. The firm cited the company's strong clinical pipeline, including AX-0811, and expert validation of its therapies for genetic disorders.
1 min readH.C. Wainwright reduced its price target for ProQR Therapeutics (NASDAQ:PRQR) to $8.00 from $12.00, citing execution risks and regulatory uncertainties. The stock is currently trading at $1.66, down 18% year-to-date. ProQR presented initial data for AX-0810, showing promising safety and biomarker engagement. Analysts maintain a positive outlook, with BofA Securities and Citizens also assigning Buy ratings and $8.00 price targets.
2 min readProQR Therapeutics (PRQR) reported Q2 2026 results, including a net loss of €8.7M and first clinical validation of its Axiomer platform. The company raised $59.2M in June and expects cash to last through mid-2028. AX-0810 showed promising Phase 1 data, and AX-0811 data is due by year-end. PRQR shares are up 7.28% to $2.38.
2 min readBank of America initiated coverage of ProQR Therapeutics (PRQR) with a buy rating, citing validation of its Axiomer RNA-editing platform. The bank set a $8 price target, implying a ~260% return from the August 19 close.
1 min readProQR Therapeutics N.V. (PRQR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ProQR Announces Second Quarter 2026 Operating and Financial Results · First clinical validation of Axiomer™ RNA editing established through NTCP modulation with positive AX-0810 clinical target engagement data; full Phase 1 dataset to be presented at a medical or sci
3 min readde Boer Daniel Anton (Chief Executive Officer) purchased 200,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.77 ($0.35M total) on 2026-07-31.
1 min readFilius Bart purchased 150,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.72 ($0.26M total) on 2026-07-17.
2 min readde Boer Daniel Anton (Chief Executive Officer) purchased 150,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.74 ($0.26M total) on 2026-07-09.
1 min readde Boer Daniel Anton (Chief Executive Officer) purchased 150,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.59 ($0.24M total) on 2026-07-07.
1 min readFilius Bart purchased 150,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.54 ($0.23M total) on 2026-06-26.
2 min read
